Pego Pérez, Emilio RubénFernández Rodríguez, IsaacPumar Cebreiro, José Manuel2025-02-172025-02-172018-06Pego Pérez, E.R., Fernández Rodríguez, I. & Pumar Cebreiro, J.M. (2018). Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review. Urologic Oncology: Seminars and Original Investigations, 36(6), 272-282. doi: https://doi.org/10.1016/j.urolonc.2018.03.0091078-1439https://hdl.handle.net/10347/39675Introduction and objective Prostate cancer (PCa) is the second most common cancer in men especially after 50 years old. The metastasis of said cancer involves a rise for morbidity, metastasizing 90% of the occasions on bone. Metalloproteinases (MMPs) are involved in the process of bone formation and they are postulated to be involved in the process of metastasizing, in particular MMP-9. This work is justified taking into account the scientific interest of the subject and the quality of the literature sources used. PCa generates a high morbidity and mortality in men, especially due to the process of metastasis, resulting in effects to health and socioeconomic level. Methods This search was performed selecting articles published from 2003 to 2017. Items were selected and valued according to the Cochrane criteria (2011). Findings and conclusions The selected articles (17) demonstrate the involvement of MMP-9 as a modulator of bone metastatic lesions either of osteoblast, osteoclast or mixed origin as well as the recognition of the major mechanisms or molecules involved in the regulation of expression gene of MMP-9 and finally establishing the MMP-9 as a therapeutic target for possible future drug development. Finally, this study evidences MMP-9 as an essential factor for the activation of the chain of the different MMPs and consequently in the genesis and development of bone metastasis of PCa due to its influence on bone osteoblastic and osteoclastic activity.engAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/MetalloproteinasesMMP-9CancerProstateBoneTherapeutic targetsInvestigaciónjournal article10.1016/j.urolonc.2018.03.009open access